Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Condition(s) targeted: Myelodysplastic Syndromes

Intervention: VORINOSTAT (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Groupe Francophone des Myelodysplasies

Official(s) and/or principal investigator(s):
Thomas PREBET, MD, Principal Investigator, Affiliation: Groupe Francophone des Myelodysplasies
Norbert VEY, MD, Study Director, Affiliation: Groupe Francophone des Myelodysplasies

Overall contact:
Thomas PREBET, MD, Phone: 00 33 4 91 22 36 95, Email: prebett@marseille.fnclcc.fr

The purpose of this study is to determine the maximum tolerated duration and schedule of oral VORINOSTAT in addition to low dose cytarabine in the treatment of Intermediate-2 and High risk myelodysplastic syndromes.

Official title: A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes

Study design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety Study

Primary outcome: To determine the Maximum tolerated dose of the association

Secondary outcome: To determine the clinical activity of this association

Detailed description: This is a multi-center, open-label, non-randomized, Phase I/II study. Patients will be treated either with arm A or B dosing schedules which contain increasing durations of exposure to vorinostat. LD Ara-C will be administered once daily, subcutaneously(SC), at 10 mg/m² in Cycle 1 and escalated to 20 mg/m² daily in Cycle 2 and above for 14 out of 28 days. Oral vorinostat will be administered as 400 mg, once daily either sequentially(Arm A) or concurrently (Arm B) with LD Ara-C in Dose Level #1 for 7 days, Dose Level #2 for 10 days, or Dose Level #3 for 14 days out of each 28-day cycle. Patients who do not have disease progression and who continue to meet eligibility criteria may receive up to 3 additional 28-day cycles of treatment.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients must meet all of the following criteria to participate in the study:

1. Patient has MDS including the following FAB sub-types: refractory anemia with blast excess (RAEB) ,transformed refractory anemia with blast excess (RAEB-t) and non proliferative Chronic MyeloMonocytic Leukemias (WBC below 13G/l).

2. Patient has a IPSS score > 1. 5 (INT-2 and high risk categories).

3. Patient is male or female, and ≥ 18 years of age on day of signing informed consent.

4. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (See Appendix 6. 1).

5. Patient has recovered from toxicities due to prior therapy (less than grade 2) except for cytopenia

6. Patient must have adequate organ function as indicated by the following laboratory values: serum creatinine <2mg/dl; total bilirubin <2,5ULN; AST<2,5ULN, ALT<2,5ULN, PAL<5ULN

7. Patient is known to not be refractory to platelet transfusions.

8. Female patient of childbearing potential has a negative serum pregnancy test (β-hCG) within 72 hours prior to receiving the first dose of vorinostat and or Ara-C . Female patient is not actively breastfeeding at the time of study entry.

9. Female patient is either post-menopausal, free from menses for > 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from becoming pregnant throughout the study, starting with Visit 1.

10. Male patient agrees to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving vorinostat and for 1 month post study.

11. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.

12. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.

13. Patient is able to swallow capsules.

Exclusion Criteria:

1. Patient had prior treatment with an HDAC inhibitor (e. g., depsipeptide or NSC-630176, MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study. Patients who have received such compounds for other indications, e. g. valproic acid for epilepsy, may enroll after a 30-day washout period.

2. Patient has been previously treated with low dose (20 mg/m2 SC daily) Ara-C for MDS within 3 months of beginning this study.

3. Patient has active and uncontrolled infection

4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.

5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.

6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.

7. Patient has clinically active hepatitis B or hepatitis C infection.

8. Patient has a known allergy or hypersensitivity to any component of vorinostat or Ara-C.

9. Patient with a "currently active" second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse.

10. Patient has received growth factors such as epoetin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required.

11. Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤ 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs

12. Patients with clinical evidence of CNS leukemia.

13. Patient has a history of GI surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.

14. Patient is unable to take and/or tolerate oral medications on a continuous basis.

Thomas PREBET, MD, Phone: 00 33 4 91 22 36 95, Email: prebett@marseille.fnclcc.fr

Hematology Dpt, Institut Paoli Calmettes, Marseille 13009, France; Recruiting
Thomas PREBET, MD, Phone: 00 33 4 91 22 36 95, Email: prebett@marseille.fnclcc.fr
Norbert VEY, MD, Phone: 00 33 4 91 22 36 95, Email: veyn@marseille.fnclcc.fr
Thomas PREBET, MD, Principal Investigator
Aude Charbonnier, MD, PhD, Sub-Investigator
Norbert VEY, MD, Principal Investigator

Hematology Dpt, Hopital Cochin, PARIS 75679, France; Recruiting
François DREYFUS, MD, Phone: 00 33 1 58 41 21 20, Email: francois.dreyfus@cch.aphp.fr
François DREYFUS, MD, Principal Investigator

Hematology Dpt, Hopital Haute Pierre, Strasbourg 67098, France; Recruiting
Shanti NATAJARAN- AME, MD, Phone: 00 33 3 88 12 76 70, Email: shanti.ame@chru- Strasbourg.fr
Shanti AME, MD, Principal Investigator

Hematology Dpt, Hopital Purpan, Toulouse 40031, France; Recruiting
Odile Beyne-Rauzy, MD, Phone: 00 33 5 61 77 96 95, Email: beynerauzy.o@chu-toulouse.fr
Odile Beyne-Rauzy, MD, Principal Investigator

Hematology Dpt, Hopital Saint Louis, PARIS 75475, France; Recruiting
Herve DOMBRET, MD PhD, Phone: 00 33 1 42 49 96 43, Email: herve.dombret@sls.aphp.fr
Herve DOMBRET, MD PhD, Principal Investigator
Emmanuel Raffoux, MD, Sub-Investigator

Hematology Dpt, Hopital de l'Hotel Dieu, Nantes 44093, France; Recruiting
Jacques DELAUNAY, MD, Phone: 00 33 2 40 08 32 71, Email: jacques.delaunay@chu-nantes.fr
Jacques DELAUNAY, MD, Principal Investigator

Hopital Avicenne, Bobigny 93009, France; Recruiting
Pierre Fenaux, MD phD, Phone: 00 33 1 48 95 70 50, Email: pierre.fenaux@avc.aphp.fr
Lionel Ades, MD PhD
Pierre Feanux, MD, PhD, Principal Investigator
Lionel Ades, MD PhD, Sub-Investigator

Starting date: May 2008
Ending date: May 2010
Last updated: October 20, 2008